Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs), including diclofenac, are the mainstay of analgesic and anti-inflammatory treatment in dentistry. Diclofenac epolamine [diclofenac N-(2-hydroxyethyl)pyrrolidine; DHEP] is a diclofenac salt with greater water solubility and better cutaneous absorption properties than other commonly used forms of the drug. IBSA has recently developed a mouthwash formulation of DHEP for the topical treatment of inflammatory conditions of the oral cavity.
Objective: The aim of this study was to compare the efficacy and tolerability of DHEP mouthwash (Osmal®) with that of a reference product (commercially available diclofenac mouthwash).
Methods: This was a randomized, investigator-blind, parallel-group, controlled, phase III study that enrolled 80 patients with conditions affecting the oral cavity, characterized by an inflammatory component, and eligible for analgesic and anti-inflammatory treatment. Patients were randomized 1 : 1 to DHEP mouthwash (0.103% DHEP in aqueous solution) or to diclofenac mouthwash (0.074% free diclofenac in aqueous solution). The treatment regimen was the same in both groups: 1-minute rinse with 15 mL of mouthwash, twice daily for 7 days. Visits were scheduled at study inclusion (D0), and 3 days (D3) and 7 days (D7) after treatment initiation. During each visit assessments were made of pain severity (using a 5-point semi-quantitative scale and a 100-mm visual analogue scale [VAS]) and inflammatory signs (using a 5-point scale). The primary study endpoint was the change in pain severity scores from D0 to D3 and D7. Secondary endpoints included effects of treatment on inflammation score, quality of sleep, compliance with treatment and the safety and tolerability of treatment.
Results: The two treatment arms were homogeneous in terms of patient characteristics. The most prevalent oral condition was gingivitis. Overall both topical treatments were effective in alleviating pain and inflammation, as evidenced by decreases in pain and inflammation scores within 3 days after treatment initiation. Notably, a significantly greater proportion of patients treated with DHEP were free of pain and inflammatory symptoms at D3 compared with those treated with the diclofenac mouthwash (40% vs 20% of patients; p<0.05). Also, DHEP was associated with more marked, but not statistically significant, decreases in VAS pain scores versus baseline after 3 days' treatment. Compliance with both treatments was good and both mouthwashes were well tolerated.
Conclusion: DHEP mouthwash was at least as effective as diclofenac mouth-wash at alleviating pain and inflammation symptoms and is well tolerated in patients with painful inflammatory conditions of the oral cavity. The potential of DHEP mouthwash deserves to be investigated in a larger patient population.
Similar content being viewed by others
References
Ong CKS, Seymour RA. An evidence-based update of the use of analgesics in dentistry. Periodontology 2008; 46: 143–64
Dionne RA, Berthold CW. Therapeutic use of non-steroidal anti-inflammatory drugs in dentistry. Crit Rev Oral Biol Med 2001; 12: 315–30
Levrini L, Carraro M, Rizzo S, et al. Prescriptions of NSAIDs to patients undergoing third molar surgery: an observational, prospective, multicentre survey. Clin Drug Investig 2008; 28: 657–68
Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin 2008; 24(10): 2967–92
Kuehl KS. Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries. Clin Ther 2010; 32: 1001–14
Moore RA, Tramèr MR, Carroll PJ, et al. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. Br J Med 1998; 316: 333–8
Brewer AR, Pierchala LA, Yanchick JK, et al. Gastrointestinal tolerability of diclofenac epolamine topical patch 1.3%: a pooled analysis of 14 clinical studies. Postgrad Med 2011; 123: 168–76
Fini A, Fazio G, Orienti I, et al. Chemical properties, dissolution relationships of NSAIDs: release of diclofenac N-(2-hydroxyethyl) pyrrolidine salt (DHEP) from monoliths. Eur J Biopharm 1992; 38: 66–72
Fini A, Fazio G, Orienti I, et al. Chemical properties-dissolution relationship. IV. Behaviour in solution of the diclofenac/N-(2-hydroxyethyl) pyrrolidine salt (DHEP). Pharm Acta Helv 1991; 66: 201–3
Fini A, Fazio G, Rapaport I. Diclofenac/N-(2-hydroxyethyl) pyrrolidine: a new salt for an old drug. Drugs Exp Clin Res 1993; 19: 81–8
Fini A, Fazio G, Gonzalez-Rodriguez M, et al. Formation of ion pairs in aqueous solutions of diclofenac salts. Int J Pharm 1999; 187: 163–73
Gallacchi G, Marcolongo R. Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion. Drugs Exp Clin Res 1993; 19: 95–7
Tramèr M, Bassetti C, Metzler C, et al. Efficacia e tollerabilità di diclofenac collutorio nella chirurgia orale o parodontale. Minerva Stomatol 2001; 50: 309–14
Weinstein RI. Studio controllato a doppia cecità verso placebo su efficacia, accettabilità e tollerabilità di diclofenac collutorio nel postoperatorio orale o parodontale. Minerva Stomatol 2001; 50: 315–9
Agarwal A, Mathur S, Kothiwale S, et al. Efficacy and acceptability of 0.074% diclofenac-containing mouthwash after periodontal surgery: a clinical study. Indian J Dental Res 2010; 21: 408–12
Acknowledgements
Editorial assistance for the preparation of this manuscript was provided by inScience Communications, a Wolters Kluwer business. This assistance was funded by IBSA Institute Biochimique SA, Lugano, Switzerland. Silvia Trevisan is an employee of the study sponsor, IBSA. Giorgio Saponati is an employee of ISPharm srl, Lucca, Italy, the clinical research organization that was in charge of study planning and monitoring activities. The other authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Serafini, G., Trevisan, S., Saponati, G. et al. Therapeutic Efficacy and Tolerability of the Topical Treatment of Inflammatory Conditions of the Oral Cavity with a Mouthwash Containing Diclofenac Epolamine. Clin Drug Investig 32, 41–49 (2012). https://doi.org/10.2165/11598170-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11598170-000000000-00000